Automation has already brought our screening capability to the point where the same specimen can be used to detect a number of hereditary aminoacidurias in addition to PKU. Yet application falls far behind: only six laboratories in the U. S. now do such automated multiple testing. Regionalizing the effort could close this gap—and involve practically no increase in cost over that of screening for PKU alone.